Current studies have indicated that TET2 mutations occur in adult AML patients with a mutation frequency between 7%-10%, while in older patients (>60 years), the TET2 mutation rate could reach 19%-24% (6, 16, 17). This evidence concerns the gene TET2 and acute myeloid leukemia.